LOS ANGELES, Oct. 12, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. AADI, a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that preclinical combination data of KRAS inhibitors and nab -sirolimus will be presented during a poster session at the upcoming 34 th EORTC-NCI-AACR Symposium, taking place October 26-28, 2022 in Barcelona, Spain.